Savant Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Savant Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$212K	Buy	+18,153	New	+$297K	﹤0.01%	2167

Other funds holding MLTX

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Achmea Investment Management Zeist, Netherlands $12.6B AUM 25.68% 1-Year Est. Return

BankPlus Wealth Management Jackson, Mississippi $229M AUM 13.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bayforest Capital London, United Kingdom $67.6M AUM 26.56% 1-Year Est. Return

Savant Capital's MLTX Position: Q3 2026 in Review

Savant Capital opened a new position in MoonLake Immunotherapeutics (MLTX) in Q3 2026: 18,153 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #2167 among its holdings.

41 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

Savant Capital held 18,153 shares of MoonLake Immunotherapeutics worth $212K as of Q3 2026.
MoonLake Immunotherapeutics was a new Savant Capital position in Q3 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of Savant Capital's portfolio in Q3 2026, its #2167 holding.
41 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Savant Capital's 13F filing for Q3 2026, filed 6 Nov 2026.